Quotient Clinical expands ADME capacity

- Last updated on GMT

Related tags: Pharmacology

Quotient Clinical has expanded its clinical facility in Nottingham, UK, citing increasing demand for ADME studies.

The firm, the clinical arm of Quotient Bioresearch, has increased the number of beds in the facility by 50 per cent to 44. The expanded unit has also gained supplementary accreditation by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).

MD Mark Egerton said the expansion “underlines the strength of our Synthesis-to-Clinic platform” and will assist the continued development of the firm’s offering in early drug development.

The investment, financial details of which were not disclosed, follows shortly after the expansion of Quotient’s manufacturing, formulation and pharmaceutical analysis suite at the Nottingham site.

At the time Egerton said that the expansion was it cater for growing customer demand for the RapidFACT (Rapid Formulation development And Clinical Testing) services the firm offers through its partnership with Bend Research​.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more